You are here

Roche

Merck taps Roche for Keytruda companion diagnostic

Merck taps Roche for Keytruda companion diagnostic

Medtech Dive

companion diagnostics

Flag link:

Gilead Taps Roche Veteran Daniel O’Day as New CEO

Gilead Taps Roche Veteran Daniel O’Day as New CEO

BioSpace

Gilead Sciences

Flag link:

China approves Descovy, Harvoni, Hemlibra

China approves Descovy, Harvoni, Hemlibra

BioCentury

Gilead Sciences

Flag link:

One more shot at slowing Keytruda’s first-line lung cancer domination

One more shot at slowing Keytruda’s first-line lung cancer domination

EP Vantage

Flag link:

Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics

Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics

Xconomy

Jecure Therapeutics

Flag link:

AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena

AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena

Fierce Pharma

Flag link:

FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia

FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia

Yahoo/Guru Focus

acute myeloid leukemia

Flag link:

Roche ties up again with Ascletis — this time on a commercial partnership for hep B drug

Roche ties up again with Ascletis — this time on a commercial partnership for hep B drug

Endpoints

Flag link:

Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals

Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals

Fierce Pharma

Flag link:

Are Gilead or Roche Interested in Buying Tesaro? Company Rumored to be on the Market

Are Gilead or Roche Interested in Buying Tesaro? Company Rumored to be on the Market

BioSpace

Gilead Sciences

Flag link:

Genentech to pay Immunocore $100M to co-develop preclinical MAGE-A4 drug

Genentech to pay Immunocore $100M to co-develop preclinical MAGE-A4 drug

Fierce Biotech

Flag link:

7 drugs that raised eyebrows in Q3

7 drugs that raised eyebrows in Q3

Biopharma Dive

Clovis Oncology

Flag link:

Roche’s Tecentriq gets fast review in triple negative breast cancer

Roche’s Tecentriq gets fast review in triple negative breast cancer

Pharmaforum

triple negative breast cancer

Flag link:

Genentech details claims Sanofi partner JHL used stolen trade secrets to develop rival drugs at an 'astonishing pace'

Genentech details claims Sanofi partner JHL used stolen trade secrets to develop rival drugs at an 'astonishing pace'

Endpoints

Flag link:

Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data

Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data

Fierce Pharma

Flag link:

Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma

Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma

Fierce Pharma

follicular lymphoma

Flag link:

Novartis abandons effort for U.S. approval of biosimilar rituximab

Novartis abandons effort for U.S. approval of biosimilar rituximab

Yahoo/Reuters

Flag link:

Roche and AbbVie Push Towards First-Line CLL Treatment

Roche and AbbVie Push Towards First-Line CLL Treatment

BioSpace

clinical trials

chronic lymphocytic leukemia

Flag link:

Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab

Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab

Endpoints

Flag link:

AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE

AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE

Pharmaforum

Rituxan/MabThera

Flag link:

Pages